Convalescent Plasma News and Research

RSS

Does COVID-19 vaccination benefit those with prior SARS-CoV-2 infection?

Researchers evaluate the effectiveness of four COVID-19 vaccines against symptomatic infection, hospitalization, and death in convalescent individuals.

5 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Convalescent plasma treatment for newly diagnosed COVID-19 patients may reduce hospitalization risk

Early treatment of newly diagnosed COVID-19 patients with plasma extracted from individuals who have recovered from the disease reduces the need for hospitalization by more than 50%, according to a new nationwide clinical trial.

31 Mar 2022

How the timing and dose of different types of passive antibody treatments predict protection from SARS-CoV-2 infection

A new study has focussed on conducting a systematic search of the literature and aggregated data associated with randomized control trials of passive antibody therapy.

25 Mar 2022

Detection of immune and clotting dysfunction in plasma and saliva after SARS-CoV-2 infection

It is becoming increasingly clear that individuals recovering from acute coronavirus disease (COVID-19) may develop post-acute sequelae (Post-Acute Coronavirus Syndrome, PACS).

23 Mar 2022

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

A recent study posted to the bioRxiv* preprint server demonstrated the neutralizing capacity of existing SARS-CoV-2 vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineages.

22 Mar 2022

Convalescent antibodies do not enhance SARS-CoV-2 infection

Researchers investigated whether antibodies enhance severe acute respiratory syndrome coronavirus-2 infection.

16 Mar 2022

Study shows the mutations leading to omicron variant did not help virus escape recognition by T cells

People who gained immunity -; either through vaccination or exposure -; against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen's omicron variant.

11 Mar 2022

Cross-species infectivity of SARS-CoV-2 variants correlated with prevalence

New research discusses the role of mutations in the receptor-binding domain of the spike protein in the generation of antibody resistance and loss of vaccine efficacy.

10 Mar 2022

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

A new study examined a unique case of extended viral shedding in an immunocompromised patient that produced a series of SARS-CoV-2 immune escape mutations over a seven-month period.

8 Mar 2022

Convalescent plasma therapy shows no significant impact on COVID-19 recovery and outcomes

Researchers conduct a multi-center study involving hospitalized COVID-19 patients to gather information on the rationale use of convalescent plasma.

3 Mar 2022

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalization, says a WHO Guideline Development Group of international experts in The BMJ today.

3 Mar 2022

Understanding the evolutionary mutational patterns of chronic SARS-CoV-2 infection

In a new study, researchers elucidated the factors driving adaptive evolution in chronic SARS-CoV-2 infections.

2 Mar 2022

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralizing ability of a polyclonal equine antibody (Ab), FBR-002, against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), including Omicron.

28 Feb 2022

Protective immunity signatures provided by convalescent plasma for the development of COVID-19 antibody therapeutics

Researchers conducted a comprehensive and systematic analysis of functional SARS-CoV-2 antibody profiles in a controlled randomized trial of severe COVID-19 hospitalized individuals treated with COVID-19 CCP.

25 Feb 2022

A comparison of COVID-19 vaccines by neutralizing antibody potency

Researchers use an international standardized assessment method to compare the efficacy of antibody responses to the major COVID-19 vaccines.

24 Feb 2022

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

A new review paper published in PLoS Pathogens discusses the new variants and the structural mechanism underlying antibody-mediated neutralization as well as mutational antibody escape.

21 Feb 2022

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Researchers select and study an RDV-resistant virus by serial passaging of wild type SARS-CoV-2 in the presence of increasing concentrations of RDV.

15 Feb 2022

Study demonstrates associations between COVID-19 symptom presentation and antibody assay reactivity

Researchers tested convalescent sera from individuals who had recovered from SARS-CoV-2 infection to demonstrate an association between antibody response and reported COVID-19 symptoms.

14 Feb 2022

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

A recent paper by researchers from Australia, currently available on the medRxiv* preprint server, shows how Immunoglobulin A (IgA) antibodies in individuals who were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to the neutralization of the virus and its variants, even though this response is heterogeneous and less potent when compared to IgG antibodies.

13 Feb 2022